Korean biotech known for PDRN-based Rejuran skin-booster injectables, alongside a pharmaceutical and cosmetic-ingredient business.
Korean biotech known for PDRN-based Rejuran skin-booster injectables, alongside a pharmaceutical and cosmetic-ingredient business.
Sells Rejuran to aesthetic clinics, which buy it for injection on their patients, with a growing part exported through local distributors; the older pharmaceutical line (Placentex) and PDRN supply to cosmetics makers give income beyond the clinics. Because the same core ingredient is used across all lines, patent protection and regulatory approvals in each country matter.
Moat: narrow (IP / patents, brand). Patented PDRN regenerative technology behind the globally popular Rejuran skin-booster brand.
Headquarters: Seongnam, South Korea · Founded: 2000 · Employees: 526
Size PharmaResearch (214450.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $2.10B, the 134th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩265,000 on 18 Nov 2026.
Performance Over six months the shares fell 24.5%, against +2.8% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 29.0% over the last twelve months (peer median +10.7%); the operating margin is 37.1% (peer median 14.7%).
Valuation It trades at 15.4× forward earnings against a peer median of 25.2× (6th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +38%, so the hurdle is -49 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 26.0 points above its cost of capital (5.5% WACC).
Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩640B | ₩536B | ₩350B | ₩261B | ₩195B |
| Revenue growth | — | +53% | +34% | +34% | — |
| Gross profit | ₩480B | ₩402B | ₩242B | ₩182B | ₩134B |
| EBITDA | ₩255B | ₩228B | ₩140B | ₩104B | ₩76.7B |
| Net income | ₩167B | ₩165B | ₩92.0B | ₩76.6B | ₩40.6B |
| Free cash flow | ₩105B | ₩154B | ₩102B | ₩52.9B | ₩42.2B |
| Capital expenditure | ₩52.3B | ₩35.8B | ₩38.7B | ₩13.2B | ₩17.8B |
| Total debt | ₩240B | ₩214B | ₩209B | ₩34.3B | ₩66.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| PharmaResearch 214450.KS | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% |
| Hugel 145020.KS | $1.69B | -30% | +17% | 38% | 18.1× | -12.1% |
| CLASSYS 214150.KS | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% |
| Caregen 214370.KS | $982M | -74% | -2% | 20% | 21.5× | 36.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 214450.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.4% | -0.9% | 11th highest of 21 |
| 6-month return | -24.5% | +2.8% | 4th lowest of 21 |
| Distance from 52-week high | -52.8% | -26.1% | 2nd lowest of 21 |
| Revenue growth (TTM) | +29.0% | +10.7% | 4th highest of 20 |
| Operating margin | 37.1% | 14.7% | highest of 19 |
| Forward P/E | 15.4× | 25.2× | 6th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -11.0% | 1.5% | least demanding of 15 |
| Growth delivered (Del g) | +37.6% | +12.3% | 3rd highest of 15 |
| Hurdle (Req g minus delivered) | -48.6 pp | -4.7 pp | 3rd least demanding of 15 |
| ROIC minus cost of capital | +26.0 pp | -1.1 pp | highest of 19 |
| EV / EBITDA | 9.9× | 16.6× | 4th cheapest of 9 |
| Net debt / EBITDA | -1.2× | 1.2× | 3rd least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% | +15.7% |
| InnoCare Pharma 688428.SS | China | $2.07B | -7% | +135% | 35% | 85.7× | -10.9% | +344.2% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% | +0.3% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% | +6.5% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | n/a | -2.5% | -5.8% |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 55.2× | 41.3% | +27.7% |